BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vaccinex\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vaccinex\, Inc.'s drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05102721-741@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pepinemab: Phase 1/2 readout est. (NCT05102721)
DESCRIPTION:Pepinemab\, phase 1/2.\nStudy: Trial of Immunotherapy With Avel
 umab and Pepinemab As Second Line For Patients With Metastatic Pancreatic 
 Adenocarcinoma\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pepinemab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05102721
URL:https://assetmemo.bio/drug/pepinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
